Sunday, February 12, 2017 9:48:48 PM
There is no evidence that the studies have been challenged. On the contrary, the preclinical testing and double blind placebo controlled 6 month study in which Sucanon outperformed Glyburide was reviewed by the Mexican and Peruvian governments and formed the basis for approval of Sucanon. In fact for all your misrepresentation of an FDA ban, FDA states in their response letter:
1. Sucanon is considered a drug per the food and drug act
2. Sucanon has been subject to "substantial clinical investigations" directly citing the published studies
3. They did not review safety and efficacy data at all
4. Sucanon would have to be submitted as an investigational new drug application
In addition, your implication in a long ago post that you found information on Sucanon from a list of criminal investigations, that information has been debunked, as has the modified Consumer Reports article that was falsely made to appear that the company was warned for illegal marketing.
As a reminder, I post publicly verifiable information to back up each and every one of my claimed facts.
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM